CRXT - Clarus Therapeutics jumps over 50% after securing new U.S. patents for Jatenzo

Clarus Therapeutics Holdings (NASDAQ:CRXT) announces that the USPTO has issued two new patents for claims that cover Clarus’ oral testosterone replacement product, Jatenzo (testosterone undecanoate). Shares up 51.4% premarket at $7.89. Patent No. 11,179,403 entitled “Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same” and patent No. 11,179,402 entitled “Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same” both cover Clarus’ approved product Jatenzo. The new patents will expire in 2030 and 2026, respectively. Jatenzo is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions.

For further details see:

Clarus Therapeutics jumps over 50% after securing new U.S. patents for Jatenzo